Literature DB >> 23948062

Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Rachel B Salit1, Daniel H Fowler, Robert M Dean, Steven Z Pavletic, Frances T Hakim, Seth M Steinberg, Nancy T Hardy, Claude Sportes, Ronald E Gress, Michael R Bishop.   

Abstract

Reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (RIC-alloHSCT) is associated with lower toxicity but higher rates of prolonged mixed chimerism than myeloablative conditioning. Decreased pretransplantation host T cell numbers are associated with less graft rejection and early full donor chimerism. To compensate for variability in pretransplantation host lymphocyte numbers and facilitate the achievement of rapid full donor chimerism, we tested a strategy of targeted lymphocyte depletion (TLD) using chemotherapy at conventional doses to provide cytoreduction and lymphocyte depletion before RIC-alloHSCT. In our study, 111 patients with advanced hematologic malignancies received 1 to 3 cycles of conventional-dose chemotherapy to reduce circulating lymphocytes to a predetermined level. Patients then underwent RIC-alloHSCT from HLA-matched siblings. Patients received a median of 2 cycles of TLD chemotherapy, resulting in a median 71% decline in CD4(+) count. All patients engrafted; there were no late graft failures. By day +14, median CD3(+) chimerism was 99% donor and was significantly associated with lower post-TLD CD4(+) counts (P = .012). One- and 5-year treatment-related mortality were 15% and 21%, respectively. At 1-year follow-up, 66% of patients had achieved complete remission (CR) of which 92% were not in CR at the time of transplantation. Overall survival at 1 and 5 years post transplantation were 66% and 47%, respectively.
Copyright © 2013 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Engraftment; Lymphocyte depletion; Reduced-intensity transplantation

Mesh:

Year:  2013        PMID: 23948062      PMCID: PMC7511977          DOI: 10.1016/j.bbmt.2013.08.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  34 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

2.  Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.

Authors:  R L Truitt; A A Atasoylu
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

3.  Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

Authors:  Rachel B Salit; Daniel H Fowler; Wyndham H Wilson; Robert M Dean; Steven Z Pavletic; Kieron Dunleavy; Frances Hakim; Terry J Fry; Seth M Steinberg; Thomas E Hughes; Jeanne Odom; Kelly Bryant; Ronald E Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2012-02-06       Impact factor: 44.544

4.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

6.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

Review 7.  Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.

Authors:  Mitchell E Horwitz
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

8.  Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.

Authors:  E Orsini; E P Alyea; A Chillemi; R Schlossman; S McLaughlin; C Canning; R J Soiffer; K C Anderson; J Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

9.  Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation.

Authors:  F Keil; P Kalhs; X Chen; O A Haas; G Fritsch; A Chott; K Lechner; K Moser; J Ackermann; W Rabitsch; N Worel; C Mannhalter; H T Greinix
Journal:  Ann Hematol       Date:  1999-08       Impact factor: 3.673

10.  Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells.

Authors:  Markus Y Mapara; Yong-Mi Kim; Sheng-Ping Wang; Roderick Bronson; David H Sachs; Megan Sykes
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

View more
  3 in total

1.  Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Authors:  Jeannine S McCune; Paolo Vicini; David H Salinger; Paul V O'Donnell; Brenda M Sandmaier; Claudio Anasetti; Donald E Mager
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-06       Impact factor: 3.333

2.  Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.

Authors:  Sencer Goklemez; Sarfaraz Hasni; Frances T Hakim; Paolo A Muraro; Filip Pirsl; Jeremy Rose; Sarfraz Memon; Daniel F Fowler; Seth M Steinberg; Eva H Baker; Sandya R Panch; Ronald Gress; Gabor G Illei; Peter E Lipsky; Steven Z Pavletic
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

3.  Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.

Authors:  Linda M Griffith; Mark VanRaden; A John Barrett; Richard W Childs; Daniel H Fowler; Elizabeth M Kang; John F Tisdale; Harvey G Klein; David F Stroncek
Journal:  Transfusion       Date:  2018-10-26       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.